Document Detail


Biosimilars and market access: a question of comparability and costs?
MedLine Citation:
PMID:  22249657     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
This article discusses specific issues related to the market access of biosimilars. Biopharmaceuticals are complex molecules produced by living cells. Copies of these medicines, called biosimilars, are not identical to their reference medicine and therefore specific regulatory requirements apply. When considering the use of biosimilars, the question of the degree of comparability between a biosimilar and the reference biopharmaceutical needs to be considered for registration, pricing and reimbursement purposes in addition to the cost issue. To date, many key concepts (like clinically meaningful differences) remain undefined and the question of the degree of comparability is not yet resolved.
Authors:
Steven Simoens; Gilbert Verbeken; Isabelle Huys
Related Documents :
11003127 - The snake as the symbol of medicine, toxicology and toxinology.
21326487 - Use of the interlock fibered idc occlusion system in clinical practice.
7433327 - Successful management of serious disopyramide poisoning.
22175247 - Not by science alone: why orangutan conservationists must think outside the box.
3843087 - Measuring attitude toward family medicine.
22556747 - Swertia spp: a source of bitter compounes for medicinal use.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-17
Journal Detail:
Title:  Targeted oncology     Volume:  -     ISSN:  1776-260X     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101270595     Medline TA:  Target Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Onderwijs en Navorsing 2, Herestraat 49, P.O. Box 521, 3000, Leuven, Belgium, steven.simoens@pharm.kuleuven.be.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Colony stimulating factors (CSF) biosimilars. Progress?
Next Document:  The economic pressures for biosimilar drug use in cancer medicine.